The ID genotype of MDM2 40 bp insertion/deletion polymorphism was associated with lower risk of SLE

Salimi, Saeedeh; Rezaei, Mahnaz; Mohammadpour‐Gharehbagh, Abbas; Sajadian, Mojtaba; Sandoughi, Mahnaz

doi:10.1136/postgradmedj-2017-134851

Cited by 3 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Roles Of Mdm2 In Inflammation and Autoimmune Diseasesmentioning

confidence: 99%

“…Systemic lupus erythematosus (SLE) is an autoimmune syndrome associated with a high chance of developing lupus nephritis (LN) . Very recently, a case‐control study investigated the associations between MDM2 T309G and insertion/deletion (I/D) polymorphisms and SLE susceptibility in 200 patients with SLE and 206 healthy volunteers . While there was no apparent association between MDM2 T309G polymorphism and SLE, the MDM2 I/D polymorphism (rs3730485) was found to be associated with a lower risk of SLE …”

Section: Roles Of Mdm2 In Inflammation and Autoimmune Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

Targeting MDM2 for novel molecular therapy: Beyond oncology

Wang

Qin

Rajaei

et al. 2019

Medicinal Research Reviews

View full text Add to dashboard Cite

The murine double minute 2 (MDM2) oncogene exerts major oncogenic activities in human cancers; it is not only the bestdocumented negative regulator of the p53 tumor suppressor, but also exerts p53-independent activities. There is an increasing interest in developing MDM2-based targeted therapies. Several classes of MDM2 inhibitors have been evaluated in preclinical models, with a few entering clinical trials, mainly for cancer therapy. However, noncarcinogenic roles for MDM2 have also been identified, demonstrating that MDM2 is involved in many chronic diseases and conditions such as inflammation and autoimmune diseases,

show abstract

Section: Roles Of Mdm2 In Inflammation and Autoimmune Diseasesmentioning

confidence: 99%

Section: Roles Of Mdm2 In Inflammation and Autoimmune Diseasesmentioning

confidence: 99%

Targeting MDM2 for novel molecular therapy: Beyond oncology

Wang

Qin

Rajaei

et al. 2019

Medicinal Research Reviews

View full text Add to dashboard Cite

show abstract

“…Genomic DNA was isolated using a commercial extraction kit (DynaBio; Takapoozist, Tehran, Iran) according to the manufacturer’s instructions. Genotyping for MDM2 polymorphisms was done by polymerase chain reaction (PCR) or PCR‐restriction fragment length polymorphism methods as previously described (Ohmiya et al, ; Salimi, Rezaei et al, ).…”

Section: Methodsmentioning

confidence: 99%

Role of MDM2 309T>G (rs2279744) and I/D (rs3730485) polymorphisms and haplotypes in risk of papillary thyroid carcinoma, tumor stage, tumor size, and early onset of tumor: A case control study

Maruei‐Milan

Heidari

Salimi

2018

Journal Cellular Physiology

Self Cite

View full text Add to dashboard Cite

Murine double minute clone 2 (MDM2) protein plays an important role in the regulation of p53 tumor suppressor. Genetic polymorphisms of the MDM2 gene are the candidate variants in susceptibility to various cancers. In the present study, we aimed to investigate the possible effects of MDM2 309T>G (rs2279744) and I/D (rs3730485) polymorphisms on papillary thyroid carcinoma (PTC) susceptibility and clinical or pathological features of the disease. A case control study was carried out involving in a total of 131 patients with PTC and 144 healthy controls. Both cases and controls were genotyped for MDM2 309T>G and I/D polymorphisms. There was no significant difference regarding MDM2 309T>G and I/D genotypes between patients with PTC and controls in neither dominant nor recessive and allelic models. The frequency of G‐D haplotype was higher in patients with PTC and this haplotype was associated with a 1.7‐fold increased risk of PTC. The MDM2 309T>G polymorphism was associated with a higher risk of III–IV stages in patients with PTC. The MDM2 ID genotype was significantly higher in patients with PTC less than 40 years and associated with larger tumor size (≥1 cm). In conclusion, the G‐D haplotype but not MDM2 309T>G and I/D polymorphisms were associated with higher risk of PTC. MDM2 309T>G polymorphism was associated with a higher incidence of III–IV stages, however, I/D polymorphism was associated with larger tumor size and a lower age of disease occurrence.

show abstract